Hyphens Pharma International Limited (SGX:1J5)

Singapore · Delayed Price · Currency is SGD

0.3650

-0.0050 (-1.35%)

At close: Aug 14, 2026

8.96% (1Y)

Market Cap	112.75M +9.0%
Revenue (ttm)	176.89M -9.2%
Net Income	8.52M -42.7%
EPS	0.03 -42.6%
Shares Out	308.91M
PE Ratio	13.29
Forward PE	9.13
Dividend	0.02 (4.11%)
Ex-Dividend Date	May 6, 2026

Volume	919,500
Open	0.3700
Previous Close	0.3700
Day's Range	0.3650 - 0.3700
52-Week Range	0.2900 - 0.3950
Beta	0.23
Analysts	Strong Buy
Price Target	0.42 (+15.07%)
Earnings Date	Aug 19, 2026

About SGXC:1J5

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments. The Pharmaceutical and Medical Aesthetics segment markets and sells a range of pharmaceutical and medical aesthetics products, including the Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Pia... [Read more]

Industry Pharmaceutical Preparations

Founded 1998

Employees 474

Stock Exchange Singapore Exchange - Catalist

Ticker Symbol 1J5

Full Company Profile

Financial Performance

In 2025, SGXC:1J5's revenue was 177.37 million, a decrease of -9.24% compared to the previous year's 195.42 million. Earnings were 5.84 million, a decrease of -42.67%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 1J5 stock is "Strong Buy." The 12-month stock price target is $0.42, which is an increase of 15.07% from the latest price.

Price Target

$0.42

(15.07% upside)

Analyst Consensus: Strong Buy

Stock Forecasts